Devin Keller

atVenu is the world’s leading Live Event Commerce platform for live events. Continuously building and enhancing features designed for maximizing revenue, dynamically adjusting your sales footprint to meet the needs of your event, and making it easier to setup, manage, and monitor sales in real-time. atVenus platform is used at over 125,000 events each year and trusted by some of the largest companies in the industry. Were built to quickly deploy, take all forms of payment including RFID and promotions both online and 100% offline, along with concierge service capabilities and mobile ordering. Our technology combines an advanced backend system specifically built to handle the unique challenges of running live events with a seamless front-end point of sale with mobile order purchasing. Dont trust us? Ask one of our customers.

KDx Diagnostics Inc. pioneers the revolutionary URO17®bladder cancer test, poised to redefine non-invasive detection. As the co-inventor and exclusive licensee of this groundbreaking technology, KDx Diagnostics Inc. has garnered FDA Breakthrough Device Designation, CE-IVD certification, and MHRA approvals for the URO17® test. With extensive testing on thousands of samples and validation through respected peer-reviewed journals, URO17® demonstrates improved sensitivity and specificity as compared to other diagnostic tests and procedures. The URO17® urine test presents a compelling alternative to invasive diagnostics and costly imaging techniques for routine monitoring in the US, while diagnosis and monitoring for outside USA of bladder cancer, potentially setting a new gold standard in bladder cancer diagnosis and monitoring.

atVenu is the world’s leading Live Event Commerce platform for live events. Continuously building and enhancing features designed for maximizing revenue, dynamically adjusting your sales footprint to meet the needs of your event, and making it easier to setup, manage, and monitor sales in real-time. atVenus platform is used at over 125,000 events each year and trusted by some of the largest companies in the industry. Were built to quickly deploy, take all forms of payment including RFID and promotions both online and 100% offline, along with concierge service capabilities and mobile ordering. Our technology combines an advanced backend system specifically built to handle the unique challenges of running live events with a seamless front-end point of sale with mobile order purchasing. Dont trust us? Ask one of our customers.

KDx Diagnostics Inc. pioneers the revolutionary URO17®bladder cancer test, poised to redefine non-invasive detection. As the co-inventor and exclusive licensee of this groundbreaking technology, KDx Diagnostics Inc. has garnered FDA Breakthrough Device Designation, CE-IVD certification, and MHRA approvals for the URO17® test. With extensive testing on thousands of samples and validation through respected peer-reviewed journals, URO17® demonstrates improved sensitivity and specificity as compared to other diagnostic tests and procedures. The URO17® urine test presents a compelling alternative to invasive diagnostics and costly imaging techniques for routine monitoring in the US, while diagnosis and monitoring for outside USA of bladder cancer, potentially setting a new gold standard in bladder cancer diagnosis and monitoring.